by Bruce Sylvester: The antidepressant citalopram (Celexa/Cipramil, and generic) significantly reduces agitation among patients with Alzheimer’s disease, researchers reported in the Feb. 19, 2014 issue of JAMA/Journal of… read more.
by Bruce Sylvester: Topiramate, an FDA-approved anticonvulsant drug which had been shown to reduce drinking in patients committed to complete abstinence, appears to help problem drinkers whose want… read more.
Aspirin is still overprescribed for stroke prevention in atrial fibrillation (AF) despite the potential for dangerous side effects, according to research published today.
by Bruce Sylvester – Prophylactic use of the breast cancer drug anastrozole for five years reduced by 53% the development of breast cancer in post-menopausal women at high… read more.
by Bruce Sylvester – Abatacept, an FDA-approved treatment of rheumatoid arthritis could become the first targeted therapy for focal segmental glomerulosclerosis glomerulosclerosis (FSGS), a condition that usually causes… read more.
Study suggests role for brain imaging to create personalized treatment of chronic pain
Using large and frequent doses of the pain-killer codeine may actually produce heightened sensitivity to pain, without the same level of relief offered by morphine, according to new… read more.
EMA Highlights by Gary Finnegan – The EMA’s Committee for Medicinal Products for Human Use (CHMP) has a new member: Ivana Mikacic has been nominated by Croatia which… read more.
EMA Highlights by Gary Finnegan – A new Healthcare Professionals’ Working Party (HCPWP) has been created by the European Medicines Agency in an effort to secure greater input… read more.
EMA Highlights by Gary Finnegan – The European Medicines Agency (EMA) must perform a delicate balancing act as it finds itself centre stage in the on-going debate about… read more.
FDA Highlights by Bruce Sylvester – Researchers report that, in a double-blind trial involving clinically depressed patients who had not responded to at least three prior antidepressants, intravenous… read more.
FDA Highlights by Bruce Sylvester – Treatment with the antipsycotic drug haloperidol does not reduce symptoms of delirium in critically ill patients, UK researchers report.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
